Index
← The Science

Alternatives & Reform

The scientific case against beagle testing, the technologies that can replace it, and the regulatory, economic, and institutional forces that determine how fast change actually happens.

$154M
OOC market (2024)
→ $1.08B by 2031 (32% CAGR)
87%
Liver-Chip sensitivity
100% specificity, 870 chips, 27 drugs
~65%
QT false-negative rate
dog cardiac testing vs clinical TQT
10%
US AWA animal decline
FY2021–FY2024 (723k → 650k)

The Scientific Critique: Why Animal Data Misleads

The case against beagle testing is not only ethical — it is scientific. The question “Do animal studies work?” has no single answer because concordance depends on the endpoint: hazard identification, target-organ prediction, dose translation, or efficacy prediction all yield different numbers. But across multiple analyses, the evidence shows systematic gaps.

Concordance: The 71% Number and What It Hides

A heavily cited pharmaceutical industry dataset (150 compounds, 221 human toxicities) reported ~71% “true positive” concordance when combining rodent and non-rodent data. Non-rodents alone predicted ~63% of human toxicities; rodents alone ~43%. This is often cited as evidence that dogs “work.” But the number hides critical asymmetries: predictive value is uneven across organ systems, some serious adverse reactions remain hard to anticipate preclinically, and methodological bias and selective reporting can inflate apparent agreement.

The Perel Systematic Review: When Animals Say “Yes” and Humans Say “No”

A systematic review by Perel and colleagues compared animal experiment outcomes with human clinical trial results across six medical interventions and found substantial discordance. Corticosteroids for traumatic brain injury: animal studies suggested benefit, but the CRASH trial showed increased mortality in humans. Tirilazad for ischemic stroke: animal models showed benefit, but clinical trials showed no benefit and potential harm. The authors emphasize that discordance can reflect both species differences and bias in animal study design/reporting.

High-Profile Translation Failures

TGN1412 (2006)
A CD28 superagonist monoclonal antibody. Despite apparently tolerable animal dosing, first-in-human administration caused catastrophic cytokine release syndrome in six volunteers. A landmark in debates about immune predictivity and first-in-human dose selection.
Fialuridine (FIAU)
A nucleoside analog that cleared animal testing yet caused severe mitochondrial toxicity in humans — deaths and liver failure during clinical development. A textbook example of species differences in delayed toxicity mechanisms.
Vioxx (Rofecoxib)
Standard safety testing did not flag the magnitude of human cardiovascular harm prior to broad exposure. Frequently cited in critiques of preclinical predictivity for cardiovascular risk — the exact domain where beagles are considered the “gold standard.”

The QT False-Negative Problem

Dogs are central to cardiovascular safety pharmacology for QT prolongation and arrhythmia liability. Yet a large retrospective analysis using the HESI/FDA database found that among 150 drugs, 43 were positive in clinical Thorough QT studies — and 28 of those 43 (~65%) had no evidence of QT prolongation in preclinical testing including in vivo dog assays. This does not mean dog studies have zero value, but it means: a negative dog QT signal is not a guarantee of human QT safety. This motivated the shift toward integrated strategies combining ion-channel panels, in silico models, and human-relevant electrophysiology (formalized in the 2022 ICH E14/S7B Q&As).

Why Beagle Results Can Specifically Mislead

Even when a dog is chosen as a non-rodent mammal with extensive background data, mechanistic differences break extrapolation. Dogs have a well-documented deficiency in arylamine N-acetyltransferase (NAT) due to absent NAT genes, which changes the metabolism of aromatic amines/hydrazines compared with humans. Canine cytochrome P450 systems show notable differences in expression and isoform composition (CYP2D, CYP2B families), affecting clearance and metabolite formation. Celecoxib shows a polymorphism in beagles leading to bimodal PK profiles (rapid vs slow eliminators), complicating dose extrapolation. Even fasting intestinal pH differs between dogs and humans, undermining direct absorption predictions for pH-dependent drugs.

The Reproducibility Crisis in Animal Research

Independent of species choice, meta-research shows that animal studies often underreport randomization, allocation concealment, and blinding — and these shortcomings are associated with exaggerated effect sizes. Industry replication efforts have shown that many “promising” preclinical findings do not reproduce. The practical implication: “better species selection” cannot, by itself, solve problems caused by weak study design, publication bias, and endpoint flexibility. Typical dog study group sizes (4/sex/group per OECD TG 409) cannot reliably detect low-incidence adverse events (1-in-100 or 1-in-1,000 toxicities).

Key Finding
The case is not that animal testing “never works” — it is that predictive value is uneven and overestimated, that the ~65% QT false-negative rate undermines the strongest claim for beagle use, and that cumulative design weaknesses (small n, lack of blinding, selective reporting) inflate apparent concordance. The question is whether we can do better — and for many endpoints, the answer is increasingly yes.

Organ-on-a-Chip Technology

Microphysiological systems (MPS) combine human cells with microfluidics and engineered physical cues to reproduce organ-relevant functions on microengineered platforms. A foundational lung-on-chip study demonstrated a microdevice reproducing the human alveolar–capillary interface, showing that mechanical strain modulates inflammatory and toxic responses — capturing dynamic physiology that static cell cultures miss entirely.

Liver-Chip: The Breakthrough Validation

A large, independent, blinded study tested 870 chips across 27 drugs and found 87% sensitivity and 100% specificity for predicting drug-induced liver injury (DILI). This is the most rigorous organ-chip validation study published to date. Economic modeling argues that improved early DILI detection could meaningfully reduce the costly late-stage attrition that currently drives the ~$2.6 billion average cost per approved drug. In 2024, the FDA accepted the first organ-on-chip technology into its ISTAND pathway for DILI-related context of use — a formal signal of regulatory confidence.

Key Companies & Market

Emulate (~17% market share) — the Wyss Institute spinout behind the liver, lung, and intestine chips used in the ISTAND-accepted validation. CN Bio Innovations — multi-organ microphysiological systems linking liver, gut, and other organs. TissUse ($25M Series C) — multi-organ-chip platforms. MIMETAS — high-throughput OrganoPlate format compatible with standard lab robotics.

The global organ-on-chip market was valued at ~$154 million in 2024 and is projected to reach $1.08 billion by 2031 — a 32% compound annual growth rate. By comparison, the broader animal testing model market is estimated at ~$19.4 billion (2022). The OOC market is tiny but growing at 10x the rate of the industry it aims to replace.

Current Limitations

Limited whole-body integration: individual chips model single organs, and multi-organ systems are still early-stage. Challenges modeling complex immune-mediated idiosyncratic injury unless immune components are specifically engineered in. Variability across platforms and cell sources. Need for standardized operating procedures (OECD’s GIVIMP guidance exists precisely for this). Inter-lab reproducibility is the critical gate to regulatory acceptance.

Organoids & 3D Cell Cultures

Organoids and 3D microtissues preserve differentiated function and multicellular architecture that 2D cell cultures cannot. They sit between flat-dish assays and full organ-on-chip systems — biologically richer than the former, simpler and more scalable than the latter.

Liver Organoid Screening

A high-throughput liver organoid platform published in the Journal of Hepatology demonstrates that organoids retain metabolic function and allow phenotypic clustering across drug injury mechanisms — supporting mechanistic risk stratification beyond simple cytotoxicity assays. This goes beyond “dead or alive” readouts to distinguish steatosis, cholestasis, and mitochondrial injury patterns, giving regulators more actionable data than a single NOAEL from a dog study.

Hybrid Organoid-on-Chip Systems

The next frontier combines organoid biology with chip-based perfusion and vascular barriers. Recent work describes liver organoid-on-chip platforms that support metabolism and hepatotoxicity testing while explicitly evaluating species-specific responses for benchmark hepatotoxins. These hybrids aim to capture the biological richness of organoids and the dynamic physiology of microfluidics — addressing a core limitation of each approach used alone.

Strengths and Limitations

Strengths: Can incorporate patient-derived genetics, enabling personalized toxicity prediction. Scalable in multiwell formats compatible with imaging and transcriptomic profiling. May capture chronic effects better than short-lived 2D cultures.

Limitations: Maturation state and lot-to-lot variability remain significant. Limited perfusion and immune components unless specifically engineered. Uncertain generalizability across diverse drug mechanisms without large, standardized reference compound sets. Regulatory replacement claims are still limited — most use today supplements rather than substitutes for animal data.

Computational & In Silico Models

CiPA: The Cardiac Safety Revolution

The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative represents the clearest pathway to replacing beagle cardiac telemetry. The 2022 ICH E14/S7B Q&As support an integrated risk assessment approach leveraging in vitro ion-channel data, in silico modeling, and human-focused evidence to inform QT/arrhythmia risk — reinforcing a trend away from relying solely on traditional in vivo dog telemetry as a universal default. For some compounds, this integrated approach can reduce or eliminate the need for clinical “Thorough QT” studies, and the same logic extends to reducing the in vivo dog component.

PBPK Modeling

Physiologically Based Pharmacokinetic models translate in vitro ADME data and human physiology parameters into predicted concentration-time profiles. Both FDA and EMA have published explicit guidance on PBPK submission content and platform qualification. A review of 2019–2023 FDA-approved drugs shows increasing use of PBPK, especially for drug-drug interaction assessment. PBPK is the mathematical bridge that makes integrated evidence packages work — it can translate exposures between systems (in vitro to predicted human dose; dog to human; chip to human).

QSAR, AI & Machine Learning

OECD has published explicit QSAR validation principles that regulators use to judge model credibility. AI/ML toxicity prediction can outperform animal models for some endpoints (cardiac pro-arrhythmic toxicity) and is explicitly contemplated in modern regulatory language: the U.S. statutory definition of “nonclinical test” now includes in silico tests and computer modeling. In 2025, ARPA-H awarded $31.7 million to Deep Origin to build in silico models explicitly aimed at replacing animal testing — the largest single federal AI-for-alternatives investment to date.

However, AI-designed drug candidates still need to clear the same decision gates (safety pharmacology + general toxicology) that regulators expect. AI is currently more likely to change where dogs sit in the pipeline than to eliminate them — optimizing candidate selection to reduce the number of compounds entering animal studies rather than replacing the studies themselves.

High-Throughput Screening (Tox21)

The Tox21 program has screened thousands of chemicals across 100+ assays with public data. Excellent for prioritization and pathway mapping, but interpreting pathway perturbations into adverse outcomes requires integration with PBPK and mechanistic models — no single NAM replaces the multi-organ readout of a dog study alone.

The Regulatory Pathway: FDA Modernization Act & Beyond

Dec 2022FDA Modernization Act 2.0Signed into law
Changed the statutory definition of "nonclinical test" to explicitly include in vitro, in silico, and in chemico methods alongside traditional animal tests. Does NOT ban animal testing — but removes the 1938 mandate that required it. Sponsors can now submit non-animal data if they choose. The key barrier shifts from "Is it legally allowed?" to "Will the reviewer accept it?"
Apr 2025FDA Phase-Out RoadmapActive policy
FDA announced a plan for animal studies to become "the exception rather than the norm" within 3–5 years, starting with monoclonal antibodies. The roadmap frames NAMs as an integrative toolkit (organ chips + computational modeling + advanced in vitro assays) and links the transition to interagency validation coordination via ICCVAM. This is the strongest regulatory signal to date.
Mar 2026FDA Draft Guidance on NAMsDraft guidance
General considerations for NAM use in drug development. Specifies validation principles: context of use, human relevance, technical characterization, fit-for-purpose performance. Signals that FDA is building the procedural infrastructure to actually accept non-animal data at scale.
Dec 2025FDA Modernization Act 3.0Passed Senate
Passed the Senate unanimously. Further advances the transition to non-animal methods with additional support mechanisms, building on the 2022 statutory change.
2035EPA Mammalian Testing DeadlineTarget date
EPA committed to eliminating mammalian testing for pesticides. Reinstated January 2026 after earlier pause. A separate but converging policy signal.
Why This Matters
The FDA Modernization Act 2.0 is the most significant structural change. Before 2022, U.S. law effectively required animal testing for drug approval — sponsors had no legal basis to substitute. Now the statute explicitly permits non-animal evidence. The practical bottleneck has moved downstream: from legal authority to reviewer confidence, validation standards, and institutional habit. Every subsequent milestone (the 2025 roadmap, 2026 draft guidance, Mod Act 3.0) is about closing that gap.

Global Regulatory Signals

The shift is not U.S.-only. Multiple jurisdictions are building NAM pathways, though at different speeds and with different motivations.

European Union
The most statistically transparent region (annual reporting under Directive 2010/63/EU). EU+Norway reported 8.39M animals used for the first time in procedures in 2022, with a ~5% decrease since 2018. 3Rs framework is legally embedded, but REACH chemical testing requirements still drive some in vivo work.
Japan (PMDA)
Japan’s Pharmaceuticals and Medical Devices Agency has a dedicated NAMs page describing in chemico, in vitro (including organoids and MPS), and in silico methods as expected to reduce reliance on animal testing. Supplier surveys show ~3.2M animals supplied in FY2022.
China
NMPA cosmetics guidance (effective May 2021) supports safety evaluation modernization that can reduce animal testing in cosmetics. But China’s large biomedical sector and lack of published annual totals (~16–20M animals estimated from 2010-era surveys) make the overall trajectory uncertain.
India
Prohibited cosmetic animal testing in 2014. But India’s own regulator (CPCSEA) stated in 2022 that “no data is available” for the number of animals used for experimentation nationally — despite 1,800+ registered establishments. A striking transparency gap.

2025: The Turning Point

NIH Closes Last Beagle Lab (May 2025)
Ending a 40-year program. White Coat Waste Project alleged NIH killed more than 2,133 beagles in septic shock experiments. The published canine sepsis model by Minneci et al. describes sedated, mechanically ventilated dogs undergoing intrabronchial bacterial challenge and 96-hour ICU-like support.
Congress Directs VA to End Dog Experiments
VA must end experiments on dogs, cats, and primates by 2026. VA dog usage had already declined from ~700 to 9 dogs over 19 years.
Gallup: Americans Split on Animal Testing
Gallup’s long-running moral issues trend shows Americans are now roughly split on whether medical testing on animals is morally acceptable, with acceptance declining substantially since 2001.

Why Change Is Slow: The Four Barriers

Regulatory Conservatism
Regulators evaluate tools in a “fit-for-purpose” manner: the same assay can be good enough for screening but insufficient for replacing a pivotal in vivo study. The evidentiary bar for replacement is higher than for addition. FDA has ISTAND and DDT qualification pathways, EMA has CHMP qualification procedures — but the processes are slow, resource-intensive, and endpoint-specific.
Historical Controls Trap
Decades of beagle data create a self-reinforcing loop: historical control baselines are strongest in dogs, so reviewers are most comfortable interpreting dog data, so sponsors perceive lower regulatory risk using dogs, so more dog data accumulates and alternative baselines lag further behind. Breaking this loop requires explicit regulatory signals — which is what the 2025 FDA roadmap attempts.
Liability Calculus
Using dogs is “low novelty” and easier to defend under precedent. Using NAMs may be scientifically strong but requires additional justification and bridging. Failures from novel methods are more reputationally salient than failures from the default approach. The incentives are asymmetric: the downside of innovating exceeds the downside of following convention.
Industry Inertia & CRO Economics
Large CROs (Charles River, Labcorp, Inotiv) have industrialized dog study templates, telemetry platforms, and global capacity. Their business models depend on animal testing revenue (Charles River: ~21% of total revenue from Research Models & Services in 2025). CRO capacity is still expanding globally — including new dog-capable facilities in China, India, and Eastern Europe — even as policy pressure grows in the US and EU.

2026–2046 Outlook: Three Scenarios

There is no single “future of animal testing.” The trajectory depends on whether NAM validation achieves regulatory-grade confidence for systemic endpoints, or remains confined to screening and well-bounded contexts. Three scenarios capture the range, each anchored to current evidence and stated regulatory intent.

Rapid Decline

Global animal use index (2025 = 100): 2031: 60–80 | 2036: 35–60 | 2046: 10–30

A strong regulatory convergence forms around “human-relevant evidence by default.” FDA guidance becomes operationalized across divisions; EU adopts NAM-first decision frameworks; PMDA builds NAM pathways into processes; China expands acceptance of validated non-animal packages. MPS + AI integration reaches high reliability for multiple systemic endpoints, enabling frequent waivers of chronic animal studies. Dog numbers in the US/EU could fall 70–90% from 2025 levels.

Gradual Decline

Global animal use index (2025 = 100): 2031: 85–95 | 2036: 70–85 | 2046: 45–70

NAMs expand steadily in early screening, certain QC tests, and defined toxicology endpoints. Animal use falls but remains substantial because chronic/systemic endpoints and complex disease models still rely on animals, and because regulatory harmonization is partial. This scenario resembles the observed EU pattern of ~5% decline over five years. Dog numbers down 35–65% by 2035, with minipig substitution continuing to erode the beagle-specific share.

Persistence

Global animal use index (2025 = 100): 2031: 95–105 | 2036: 90–105 | 2046: 80–105

NAMs grow but remain additive rather than substitutive: they increase efficiency and reduce some categories, yet total biomedical R&D volume grows and new modalities (biologics, ADCs, gene/cell therapy) keep animal studies central. Regulatory agencies accept NAMs selectively but do not treat them as default replacements. Animal use is near-flat through 2046.

Methodology Caveat
Two variables dominate the spread between these scenarios: (1) whether NAM validation extends to chronic/systemic endpoints by ~2036 — because ICH guidance still presumes animal studies for these, and (2) whether the growth in novel modalities (biologics, ADCs, gene/cell therapy) outpaces NAM coverage, creating new demand for specialized in vivo models even as older demand recedes.

Transition Timeline: What Changes When

Replacement will happen by segment, not all at once. The pace depends on whether the endpoint is localized and mechanistically well-characterized (faster) or systemic, chronic, and immunologically complex (slower).

By 2030: Already Replaceable or Nearly So

• Skin corrosion/irritation and some sensitization pathways (well-bounded biology, high reproducibility)

• Acute toxicity screening and mechanistic flagging via HTS + in silico

• Some biologics safety packages, starting with monoclonal antibodies (FDA roadmap)

• DILI prediction via qualified Liver-Chip (ISTAND pathway)

• Some QC tests (pyrogen/bacterial endotoxin) already replaced

• Cardiac risk assessment increasingly handled by CiPA-style integrated strategies

By 2035: Significant Reduction, Not Elimination

• Many standardized regulatory hazard tests likely replaced by integrated NAM panels

• PBPK + organ-chip + AI panels accepted for more drug submission contexts

• Dog numbers in US/EU potentially down 35–65% from 2025 levels (gradual-to-rapid scenario)

• Minipig substitution continues to erode the beagle-specific share of remaining dog studies

• Global OOC market potentially $1B+ with standardized, multi-site platforms

• EPA mammalian testing elimination deadline for pesticides

By 2046: Replacement-by-Segment, Not “End of Animal Testing”

• Many standardized hazard tests largely replaced

• Continued animal use for some advanced modalities, unresolved endpoints, and complex disease models

• Shifting species mix: fewer dogs and rabbits for some tests; persistent rodent use; reduced but continuing NHP use

• Total elimination of animal testing is not a plausible 20-year outcome for all endpoints

• Global use index: 10–30 (rapid), 45–70 (gradual), 80–105 (persistence) vs 2025 baseline of 100

What “Replacement” Actually Means — and What It Does Not

The word “replacement” is used loosely in advocacy, precisely in regulation, and differently by scientists. Getting this right matters because overpromising undermines credibility and underpromising surrenders achievable ground.

What It Means

Endpoint-specific substitution: For a defined regulatory question (e.g., “Does this drug cause liver injury?”), a non-animal method produces equal or better decision quality. The Liver-Chip DILI validation is the current best example.

Integrated evidence packages: A combination of NAMs (chip + PBPK + in silico + human cell assays) covers the same decision space that a dog study was supposed to cover — not one-for-one, but collectively. The FDA’s 2025 roadmap explicitly frames the transition this way.

Segment-by-segment transition: Some endpoints are replaceable now, others by 2035, others not in any foreseeable timeline. The realistic goal is progressive elimination of the weakest-justified animal uses first.

Legal permissibility: Since December 2022, U.S. law no longer mandates animal testing. Sponsors can submit non-animal data. This is a necessary but not sufficient condition.

What It Does Not Mean

A single technology replaces all animal testing: No chip, no algorithm, no organoid covers the full spectrum of safety and efficacy questions. Replacement requires a portfolio of methods, each validated for specific contexts of use.

Immediate elimination: Even under the most optimistic scenario, animal testing persists for complex systemic endpoints, developmental/reproductive toxicity, and some advanced therapies through 2046. The FDA’s own roadmap is “stepwise” and “method-validation dependent.”

That current alternatives are perfect: Organ-chips lack whole-body integration. AI models inherit training-data biases. Organoids have maturation variability. The honest position is that these are better than dogs for some questions and worse for others — and the frontier is moving.

That animal testing “works fine” and replacement is unnecessary: The ~65% QT false-negative rate, the translation failures (TGN1412, FIAU, Vioxx), and the reproducibility crisis in animal research demonstrate that the status quo has serious predictive gaps. The question is not “Should we replace?” but “How fast can we validate better methods?”

What Is NOT Being Replaced Yet

Cardiovascular Telemetry (In Vivo)

The ICH S7A/S7B framework requires assessment of cardiovascular effects in a conscious, instrumented non-rodent species. CiPA and integrated approaches are opening space, but no organ-on-chip or computational model has been validated as a complete replacement for the conscious telemetered dog for all drug classes. The irony: the animal model itself has a ~65% false-negative rate for QT, yet it remains the regulatory default because the alternatives haven’t cleared the same evidentiary bar.

Chronic Systemic Toxicology

Multi-organ effects developing over months of repeated exposure. No in vitro system captures the full integration of absorption, distribution, metabolism, excretion, immune response, endocrine feedback, and neurohumoral loops that produce chronic toxicity in a whole organism. Multi-organ-chip systems are pursuing this, but standardization and regulatory acceptance are years away.

Developmental & Reproductive Toxicity (DART)

Testing whether a drug harms embryos, fetuses, or reproductive function. Requires modeling pregnancy, placentation, organogenesis, and multi-generational effects. Guidance still points to animal use in relevant species. NAMs may chip away at specific contexts (embryonic stem cell tests for teratogenicity screening) but cannot yet replace the full DART battery.

Complex Immune-Mediated Toxicities

Idiosyncratic drug reactions, hypersensitivity, and autoimmune-like responses involve interactions between the drug, the immune system, and specific patient genetics. Neither animal models nor current NAMs predict these reliably. TGN1412 is the cautionary example: no species — animal or in vitro — flagged the catastrophic human response.

Data Gap
The least-visible dog use is contracted, sponsor-owned nonclinical work that never becomes a journal article. GLP toxicology and safety pharmacology are designed to support regulatory decisions, and most detail lives in proprietary study reports. Public visibility occurs only after success — through redacted regulatory reviews for approved products. Failed candidates are invisible. Global geographic shifts in dog testing capacity (to China, India, Eastern Europe) are real but impossible to quantify for severity because severity classifications are not harmonized internationally.

Sources

Olson et al. (2000): Concordance of the toxicity of pharmaceuticals in humans and animals. Regulatory Toxicology and Pharmacology, 32(1), 56-67.

Perel et al. (2007): Comparison of treatment effects between animal experiments and clinical trials. BMJ, 334:197.

HESI/FDA QT database analysis: Evaluation of drug-induced QT interval prolongation. PMC4543608.

Liver-Chip validation: Ewart et al. (2022). Nature Communications Biology, s43856-022-00209-1.

ICH E14/S7B Questions & Answers (2022): Integrated risk assessment for QT/TdP.

ICH S7A: Safety Pharmacology Studies for Human Pharmaceuticals.

FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies (April 2025).

FDA Draft Guidance: General Considerations for the Use of NAMs in Drug Development (March 2026).

FDA Modernization Act 2.0 (2022): 21 USC statutory definition of “nonclinical test.”

FDA Modernization Act 3.0 (2025): Passed Senate unanimously, December 2025.

OECD GIVIMP: Guidance Document on Good In Vitro Method Practices.

Taylor & Alvarez (2019): Estimated global animal use. Alternatives to Laboratory Animals, 47(5-6), 196-213.

USDA APHIS FY2021–FY2024 Research Facility Annual Report Summaries.

EU+Norway 2022 Statistical Report under Directive 2010/63/EU (ALURES).

Charles River Laboratories 2025 Annual Report (Research Models & Services segment).

ARPA-H award to Deep Origin (2025): $31.7M for in silico models replacing animal testing.

PMDA NAMs page: In chemico, in vitro, and in silico methods for drug development.

CPCSEA (India) 2022 communication: National registry on experimental animals.

NMPA (China) 2021: Cosmetics safety evaluation guidance, effective May 1, 2021.